Anupam Rasayan Q1 FY27: Strong consolidated growth, with integration and new chemistries in focus

Anupam Rasayan India Limited started FY27 with a sharp jump in consolidated scale, helped by new product commercialization and the first full-year consolidation runway for its US acquisition, Jayhawk Fine Chemicals. In Q1 FY27, consolidated total income rose to INR 667.5 crore, up 36% year-on-year. Consolidated EBITDA increased 35% to INR 174.9 crore, and the EBITDA margin stayed stable at 26%.

Profit growth, however, was much slower than operating growth. Consolidated PAT was INR 51.2 crore, up 6% year-on-year, with PAT margin at 8% versus 10% last year. Management attributed the weaker flow-through to higher depreciation from the expanded asset base and Jayhawk depreciation, as well as the impact of financing costs.

A quarter where growth came from the platform, not just the base business

The presentation makes an important distinction between standalone and consolidated performance. Standalone total income in Q1 FY27 was INR 334.9 crore, up 4% year-on-year. Standalone EBITDA was INR 115.5 crore, up 17%, with margins at 34%.

The consolidated jump therefore reflects the wider group structure now in place. Anupam’s corporate structure highlights four platforms: Anupam Rasayan India (custom manufacturing platform), Tanfac Industries (fluorochemicals platform), Jayhawk Fine Chemicals (advanced CDMO platform in the US), and the proposed Bliss GVS Pharma investment (finished formulations platform, transaction under progress at the time of the call).

Management also highlighted that exports contributed 36% of revenue in Q1 FY27, indicating a meaningful international business component.

Financial summary (as reported)

Jayhawk in the numbers, and why it matters

A major theme of both the investor presentation and the earnings call was the contribution from Jayhawk Fine Chemicals, acquired in the US. Management described FY27 as the first full year where Jayhawk is consolidated and integrated.

On the call, management said Jayhawk contributed around 20% to 22% of consolidated revenue in the quarter, translating to roughly INR 145 crore of revenue, and posted EBITDA margins of about 19% to 20%. Management also referenced Jayhawk PAT at around INR 9 crore, with depreciation being a key reason why accounting profit is lower than operating profit.

Strategically, the company positioned Jayhawk as a US-based platform for high-value, innovation-led end markets such as semiconductors, automotive/EV, aviation, electronics, and performance materials. The investor presentation also notes that Jayhawk has significant land headroom for expansion, with an 800-acre site and less than 10% utilized.

ETFA and flow chemistry: moving up the technology curve

The most notable technology milestone highlighted was the commercialization of ETFA (Ethyl Trifluoroacetate) using flow chemistry. The company stated it is the first globally to commercialize ETFA through flow chemistry.

Management explained flow chemistry as an enabling process technology that improves safety and reaction control, reduces environmental footprint through lower solvent and side-reaction intensity, and can support higher scale with smaller reactor footprints. Importantly, management stated that ETFA has applications across pharma, agro, electronics and semiconductor industries.

On market potential, management estimated that the market for two molecules is about USD 0.5 billion. They indicated an initial target market share of 5% to 10%, with aspirations to move higher over time, and also stated that manufacturing cost parameters should be better and therefore margin profile should be better, without giving a quantified margin.

Long-term LOIs: visibility, with ramp-up over time

A second anchor of the quarter was the signing of an LoI with BASQUEVOLT, S.A. The investor presentation described this as a potential revenue opportunity of up to USD 300 million over a 10-year period, with expected commercialization in FY27. In the LOI table, the BASQUEVOLT LoI is shown with a value of INR 2,850 crore and a 10-year tenor.

During the earnings call, management stated that the technology is already developed at lab and pilot levels, and that commercialization should start in FY27. They also set expectations that it will take 2 to 3 years to ramp up to a more stable, robust revenue level, consistent with how new products scale in custom manufacturing.

The investor presentation lists 16 additional LOIs and contracts, taking the cumulative value to INR 17,496 crore across different periods, with multiple items scheduled for commercialization from FY27 onwards. This is not the same as an order book that converts in one year, but it does provide a structured view of contracted or quasi-contracted opportunity over time.

Bliss GVS Pharma: timeline clarity, but limited operating commentary

The proposed acquisition of Bliss GVS Pharma was a key topic, but management was careful in responding to detailed operating questions as the transaction had not been consummated at the time of the call.

Management stated that SEBI approval had been received, the open offer process had been completed, and the company expected to conclude the transaction in the first half of September 2026. They also said that after consummation, the company would begin integration discussions with Bliss management.

On strategic intent, management described Bliss as a step toward regulated manufacturing and global access in formulations. They reiterated their view that capacity utilization at Bliss can be increased to 60% to 70% over 2 to 3 years, though detailed financial guidance was not provided.

Guidance: growth, margins, and capex discipline

Management provided several explicit forward-looking statements during the call:

1. Organic revenue growth is expected to be around 25% plus or minus a couple of percentage points.
2. Additional 10% to 15% growth is expected due to Jayhawk, because it was not a meaningful contributor in the base period.
3. EBITDA margin guidance was reiterated at 24% to 26% for standalone and 22% to 24% for consolidated.
4. Capex is expected to be limited after completion of the major capex cycle, guided at around INR 70 crore to INR 80 crore, largely for repairs, maintenance and limited repurposing.

The company also indicated that working capital remained largely stable in Q1 FY27 and is expected to improve through FY27, though it did not disclose a numeric working-capital-days target in the documents.

Takeaways from Q1 FY27

Q1 FY27 suggests Anupam Rasayan is transitioning into a broader, more global specialty chemicals and CDMO platform, supported by acquisitions and a deeper product pipeline. The quarter’s headline growth was strong at the consolidated level, and operating margins were stable, but PAT growth was constrained by depreciation and finance costs.

The near-term investor focus is likely to remain on three execution questions: how quickly Jayhawk can be scaled within the group, how efficiently new LOIs like BASQUEVOLT ramp up over the next few years, and how smoothly the Bliss GVS Pharma transaction closes and integrates after September 2026.